Company profile: Electra Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage monoclonal antibody therapies targeting SIRP proteins for cancer and immunological diseases. Lead candidate ELA026 is in clinical development for sHLH and preclinical for other inflammatory diseases, designed to deplete myeloid and T cells driving hyperinflammation. Additional SIRP-directed antibodies aim to deplete specific immune or tumor cells.
Products and services
- SIRP-directed Antibodies (Oncology): Custom-engineered monoclonal antibodies targeting the Signal Regulatory Protein family enable tumor cell eradication by exploiting differential SIRP expression to promote targeted depletion of malignant cells in cancer
- ELA026: Clinical-stage monoclonal antibody ELA026 targets SIRP proteins on myeloid and T cells to deplete hyperinflammation-inducing cells, in development for sHLH and preclinical evaluation in other inflammatory diseases
- SIRP-directed Antibodies (Immunology): Mechanism-driven monoclonal antibodies against SIRP family members leverage differential expression to selectively deplete specific immune cell types for treatment of immunological diseases.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Electra Therapeutics
Ception Therapeutics
HQ: United States
Website
- Description: Provider of payroll management services, delivering customizable payroll solutions and advanced software for seamless, timely processing; comprehensive administration covering tax filings and employee deductions; payroll compliance with the latest laws and regulations; and consulting on best practices and audit assistance, allowing businesses to focus on growth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ception Therapeutics company profile →
Cyxone
HQ: Sweden
Website
- Description: Provider of biopharmaceutical R&D focused on cyclotide-based drugs for severe autoimmune diseases. Operates via an international expert network across research, development and manufacturing. Pipeline includes Rabeximod, an oral Phase 2 candidate for rheumatoid arthritis targeting inflammatory macrophages, and T20K, an early clinical candidate for multiple sclerosis modulating T cell activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyxone company profile →
Valenza Biotech
HQ: United States
Website
- Description: Provider of biomarker-driven therapeutic development for autoimmune and inflammatory diseases, leveraging monoclonal antibodies that target surface antigens to reduce pathogenic subpopulations of autoreactive cells, guiding research and clinical development toward safe and effective treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valenza Biotech company profile →
Epiva
HQ: United States
Website
- Description: Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiva company profile →
YorkTest
HQ: United Kingdom
Website
- Description: Provider of food intolerance programs and diagnostic testing services, providing personalized information and support to help optimize health and wellbeing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full YorkTest company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Electra Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Electra Therapeutics
2.2 - Growth funds investing in similar companies to Electra Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Electra Therapeutics
4.2 - Public trading comparable groups for Electra Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →